Plasmalogen as Therapeutics to Neurodegenerative Disorders
Kushal Vesmaker1, Sugato Banerjee1★★ Corresponding author
- 1Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal, INDIA.
CORRESPONDENCE
Sugato Banerjee
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal, INDIA.
Received: 29-07-2022; Revised: 28-09-2022; Accepted: 09-10-2022.
Volume 15, Issue 1 · pp. 31–36 · PUBLISHED · DOI: 10.5530/097515050475
ABSTRACT
Plasmalogens, glycerophospholipids, can alleviate Parkinson's and Alzheimer's disease. It helps in neural communication, such as vesicular or membrane fusion and ion transport. It counteracts oxidative stress by acting on Reactive Oxygen Species (ROS). Plasmalogens may improve memory in Alzheimer's patients as observed using Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Plasmalogens are usually isolated from Ascidians and Scallops. In the current review, we discuss the role of plasmalogen in neurodegenerative disorders.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Vesmaker, K., & Banerjee, S. (). Plasmalogen as Therapeutics to Neurodegenerative Disorders. Journal of Young Pharmacists, 15(1), 31–36. https://doi.org/10.5530/097515050475